BioCentury
ARTICLE | Clinical News

DAG for Injection: Additional Phase I/II data

May 4, 2015 7:00 AM UTC

Data from 6 patients with refractory GBM in the 8th cohort of an open-label, U.S. Phase I/II trial showed that 50 mg/m 2 IV VAL-083 given on days 1-3 of a 21-day cycle led to dose-limiting toxicities ...